Antibodies directed to monocyte chemo-attractant protein-1 (MCP-1) and uses thereof
    2.
    发明申请
    Antibodies directed to monocyte chemo-attractant protein-1 (MCP-1) and uses thereof 失效
    针对单核细胞化学引诱物蛋白-1(MCP-1)的抗体及其用途

    公开(公告)号:US20070116708A1

    公开(公告)日:2007-05-24

    申请号:US11641633

    申请日:2006-12-19

    IPC分类号: A61K39/395 C07K16/24

    摘要: Embodiments of the invention described herein relate to antibodies directed to the antigen monocyte chemo-attractant protein-1 (MCP-1) and uses of such antibodies. In particular, in accordance with some embodiments, there are provided fully human monoclonal antibodies directed to the antigen MCP-1. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

    摘要翻译: 本文描述的本发明的实施方案涉及针对抗原单核细胞化学引诱物蛋白-1(MCP-1)的抗体和这种抗体的用途。 特别地,根据一些实施方案,提供针对抗原MCP-1的完全人单克隆抗体。 编码的核苷酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列,特别是对应于跨越框架区和/或互补决定区(CDR)的连续重链和轻链序列的序列,特别是从FR1至FR4或CDR1至CDR3 ,提供。 还提供了表达这种免疫球蛋白分子和单克隆抗体的杂交瘤或其它细胞系。

    Antibodies directed to monocyte chemo-attractant protein-1 (MCP-1) and uses thereof
    4.
    发明授权
    Antibodies directed to monocyte chemo-attractant protein-1 (MCP-1) and uses thereof 失效
    针对单核细胞化学引诱物蛋白-1(MCP-1)的抗体及其用途

    公开(公告)号:US07482434B2

    公开(公告)日:2009-01-27

    申请号:US11641128

    申请日:2006-12-19

    IPC分类号: C07K16/00 A61K39/395

    摘要: Embodiments of the invention described herein relate to antibodies directed to the antigen monocyte chemo-attractant protein-1 (MCP-1) and uses of such antibodies. In particular, in accordance with some embodiments, there are provided fully human monoclonal antibodies directed to the antigen MCP-1. Nucelotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

    摘要翻译: 本文描述的本发明的实施方案涉及针对抗原单核细胞化学引诱物蛋白-1(MCP-1)的抗体和这种抗体的用途。 特别地,根据一些实施方案,提供针对抗原MCP-1的完全人单克隆抗体。 编码Nuclotide序列和包含重链和轻链免疫球蛋白分子的氨基酸序列,特别是对应于跨越框架区和/或互补决定区(CDR)的连续重链和轻链序列的序列,特别是从FR1至FR4或CDR1至CDR3 ,提供。 还提供了表达这种免疫球蛋白分子和单克隆抗体的杂交瘤或其它细胞系。

    Antibodies directed to monocyte chemo-attractant protein-1 (MCP-1) and uses thereof
    5.
    发明授权
    Antibodies directed to monocyte chemo-attractant protein-1 (MCP-1) and uses thereof 失效
    针对单核细胞化学引诱物蛋白-1(MCP-1)的抗体及其用途

    公开(公告)号:US07687606B2

    公开(公告)日:2010-03-30

    申请号:US11641633

    申请日:2006-12-19

    摘要: Embodiments of the invention described herein relate to antibodies directed to the antigen monocyte chemo-attractant protein-1 (MCP-1) and uses of such antibodies. In particular, in accordance with some embodiments, there are provided fully human monoclonal antibodies directed to the antigen MCP-1. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

    摘要翻译: 本文描述的本发明的实施方案涉及针对抗原单核细胞化学引诱物蛋白-1(MCP-1)的抗体和这种抗体的用途。 特别地,根据一些实施方案,提供针对抗原MCP-1的完全人单克隆抗体。 编码的核苷酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列,特别是对应于跨越框架区和/或互补决定区(CDR)的连续重链和轻链序列的序列,特别是从FR1至FR4或CDR1至CDR3 ,提供。 还提供了表达这种免疫球蛋白分子和单克隆抗体的杂交瘤或其它细胞系。